Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics Incorporated received an updated ownership report from investment manager Renaissance Technologies LLC and its parent, Renaissance Technologies Holdings Corporation. As of December 31, 2025, they report beneficial ownership of 5,758,528 shares of Corcept common stock, representing 5.47% of the outstanding class.
Renaissance reports sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing notes that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds, and states the position is held in the ordinary course of business, not to change or influence control of Corcept.
Corcept Therapeutics Chief Scientific Officer Hazel Hunt reported an option exercise and related share withholding. On February 9, 2026, Hunt exercised stock options for 150,000 shares of common stock at an exercise price of $3.88 per share, converting a stock option that was fully exercisable and scheduled to expire on February 26, 2026.
To cover the option exercise price and associated tax withholding in a net (cashless) transaction, 77,968 common shares were withheld at a price of $41.31 per share. After these transactions, Hunt directly held 255,437 shares of Corcept Therapeutics common stock.
Corcept Therapeutics Chief Development Officer William Guyer reported an option exercise and share sale. On February 3, 2026, he exercised a stock option for 20,000 shares of common stock at $21.65 per share and then sold 20,000 shares at a weighted average price of $40.8667 under a prearranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, he directly held 1,235 shares of common stock and 230,000 stock options that are fully exercisable.
Corcept Therapeutics insider William Guyer has filed to sell 20,000 shares of common stock under Rule 144. The planned sale, through broker Stifel Nicolaus & Company on NASDAQ, has an aggregate market value of $814,200.00, with 105,190,000 shares of the issuer’s common stock outstanding.
The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash on the same date. Over the past three months, Guyer has sold 20,000 shares on each of three occasions, for gross proceeds of $1,601,525.00, $703,655.00, and $1,507,121.00.
Corcept Therapeutics director Leonard G. Baker Jr. reported multiple stock option exercises on January 27, 2026, converting options into blocks of 25,000–30,000 common shares at exercise prices between $5.86 and $15.15. These transactions are coded as option exercises, not open-market sales.
After the reported transactions, a trust for which he serves as trustee holds 1,095,262 Corcept common shares indirectly, and a limited partnership associated with a trust of which he is trustee holds 3,308,303 shares. He also directly holds 1,046,631 shares. The filing states he disclaims beneficial ownership in the trust and partnership shares except for his pecuniary interest.
Corcept Therapeutics announced that ROSELLA, its pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. This means the treatment combination achieved its main goal of improving how long patients live in this hard-to-treat setting. The company shared this outcome through a press release attached as an exhibit, signaling a key late-stage milestone for relacorilant in oncology.
Corcept Therapeutics Chief Development Officer William Guyer reported option exercises and share sales in company stock. On January 6, 2026, he exercised a stock option for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share. The filing notes that the sale prices ranged from $34.96 to $35.50 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. After the transactions, Guyer directly held 1,235 shares of common stock and 250,000 stock options that are reported as fully exercisable.
Corcept Therapeutics Inc. insider plans another share sale. A Form 144 notice discloses an intended sale of up to 20,000 shares of Corcept common stock through Stifel Nicolaus & Company Inc. on or about 01/06/2026, with an indicated aggregate market value of $699,000.00. The filing notes that 105,190,000 Corcept common shares were outstanding, providing context for the size of the planned transaction.
The 20,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from Corcept Therapeutics Inc., paid in cash. Over the prior three months, the same seller, William Guyer, reported three separate sales of 20,000 Corcept common shares each (on 10/07/2025, 11/05/2025, and 12/02/2025) with gross proceeds of $1,798,781.00, $1,507,121.00, and $1,601,525.00, respectively.
Corcept Therapeutics director James N. Wilson reported several internal movements of Corcept common stock among family-related entities on December 12, 2025. A family trust disposed of 400,000 shares as a gift at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust.
Two 2025 grantor retained annuity trusts each received 200,000 shares without consideration and are reported as indirectly holding 200,000 shares apiece. The report also lists 901,067 shares of Corcept common stock held indirectly through James and Pamela Wilson Family Partners, over which Wilson has voting power pursuant to voting agreements while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025. He exercised 20,000 stock options at $21.65 and sold a total of 20,000 shares in multiple trades, including 6,536 shares at a weighted average of $74.7489, 13,164 shares at $75.6365, and 300 shares at $76.28. Following these trades, he directly owned 5,287 shares and held 290,000 derivative securities (options) afterward. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.